Dear Friends of the Foundation,

“We are building this!»: On September 29, 2016, these words announced the laying of the foundation stone for the AGORA Cancer Center. The ceremony was attended by approximately one hundred distinguished scientists, representatives of universities, politicians, members of various institutions and many donators. The numerous guests present on this day reflect the tremendous interest in this innovative project which unites all actors in cancer research, just a stone’s throw from the patient’s bedside.

The first scientists and clinicians (and there will be close to 300 of them by the time the project is completed) are due to move into the AGORA building during the first half of 2018.

United against cancer
Progress made within the last 15 years (see the interview with Professor Franco Cavalli on pages 11-14), such as improved knowledge of the human genome, today enables us to treat a larger number of cancers, even though this disease is particularly skillful in outwitting the strategies deployed against it.

Yet the battle continues, and at this point in time it is very important that physicians, biologists and computer scientists communicate and work together to develop solutions that will benefit the patients. This is the enormous challenge AGORA and all its partners are called to meet.
Trust and transparency
After the death of Yves Paternot in February 2016, the Foundation Council decided to modify its governance and wished to adopt new legal and fiscal competences, two key fields required to guarantee both the source and the optimal use of entrusted funds. The multidisciplinary and international Scientific Board was enlarged to include five members (see page 25). One of its missions will be to visit the AGORA center once a year, in order to analyze ongoing projects, audition scientists and ensure that the research is truly translational and the financial effort actually benefits patients.

I wish to take this opportunity to thank the members of the boards, the management and all collaborators for their invaluable commitment to the objectives of the Foundation.

Amélie, Svenja, Efe and Pierpaolo
Supporting the next generation of scientists is another main mission of our Foundation. In this annual report, we wished to present four of the young researchers we are sponsoring. Men and women from Germany, Italy, Switzerland and Turkey, they share a same motivation and purpose in their research effort: giving hope to patients.

Patients at the heart of our concerns
The Foundation continues to closely monitor the progress made in the fight against cancer, especially with respect to novel therapies (immunotherapy in particular) and personalized medicine. The Foundation also ensures that patients suffering from this disease as well as their loved ones are informed and supported in their daily struggle.

To you all, individuals and institutions who trust and support us with your donations, the ISREC Foundation expresses its gratitude. THANK YOU from the bottom of our hearts!

Thanks to you, the Foundation can pursue its three missions, true to the values of its founders.

Catherine Laboucheère
President
The ISREC Foundation identifies, selects and supports concrete projects that promote knowledge transfer and collaborations between basic research and clinical applications. The aim is to establish novel therapeutic and diagnostic approaches and to study cells and their interactions with the environment in order to be able to act on the causes of cellular dysfunctions.

1. SUPPORTING TRANSLATIONAL RESEARCH
2. SUPPORTING YOUNG SCIENTISTS

The ISREC Foundation grants scholarships to students, PhD candidates and scientists working in the fields of biology, technology or medicine and whose work is focused on immunology and oncology.

3. AGORA – APPLIED CANCER RESEARCH CENTER

The ISREC Foundation, in charge of the construction of the AGORA – Cancer Center, strives to create a center of excellence in cancer research. This project will bring together basic science researchers and clinicians in order to accelerate the development of novel therapeutic strategies focused on patients’ needs.
Remodeled Governance

In an ever-changing economic environment, characterized by increasingly stringent international rules, the ISREC Foundation has made a point of adding financial diligence specialists and legal experts to its team. In 2016, the Foundation reinforced its governance in order to have access to the best financial and legal counsel. Four new members have therefore joined the Foundation Council in 2016: **Yves Bonzon** – member of the Julius Baer executive board, **Prof. Pierre-Marie Glauser** – lawyer and professor of tax law at the UNIL (University of Lausanne), associate at Abels Oberson SA, **Dr W. Thomas Paulsen** – CEO, Chief Financial Officer and head of the finance and risk division at the Banque Cantonale Vaudoise, and **Béatrice Schaad** – director of the CHUV communications department.

The ISREC Foundation also welcomes the appointment in February 2016 of **Catherine Labouchère**, a jurist and delegate of the Canton of Vaud parliament, as the president of the Foundation Council.

The Scientific Board, chaired by **Prof. Franco Cavalli** has also been reshaped. Four new renowned scientists have joined the project evaluating team:

- **Prof. Fabrice André**
  Specialist in the areas of cancer and new drugs. Research director, responsible for the U981 unit of the INSERM, associate professor at the medical oncology department, Institut Gustave Roussy, Villejuif, France

- **Prof. Michael Hall**
  Specialist in basic research and biochemistry. Professor at the Biozentrum, University of Basel

- **Prof. Peter Johnson**
  Specialist in the areas of lymphoma and immunotherapy. Professor of medical oncology, Faculty of Medicine, University of Southampton, UK

- **Prof. Anne Müller**
  Specialist in experimental medicine
  Associate professor of experimental medicine, Institute for Molecular Cancer Research, University of Zurich.
More than ever, the missions of the ISREC Foundation are of several kinds. First and foremost, they aim to promote cancer research projects and to ensure the academic renewal among scientists. They also contribute to the financing of scholarships for PhD students.

In 2016, the Foundation supported four PhD students: two students in the «Molecular Life Sciences» program of the École Polytechnique Fédérale in Lausanne and two students in the «Cancer and Immunology» program of the University of Lausanne. Since 2008, the ISREC Foundation also funds students participating in the UNIL and EPFL «Summer Undergraduate Research Programs». In 2016, twelve young biologists and physicians were invited to take advantage of this opportunity to make first contact with the world of research, to acquire valuable work experience and to gain the opportunity to establish new contacts on an international level.

Convinced that young scientists need backing more than ever, particularly at the beginning of their careers, the ISREC Foundation intensively supports the establishment of new professorial chairs, at the ISREC@epfl or the CHUV-UNIL. In 2016, the Foundation also financed a chair occupied by Prof. Ping-Chih Ho of the department of fundamental oncology at the University of Lausanne and the LICR.

Thanks to generous donations, the ISREC Foundation was also able to establish the launching of several research projects in translational and clinical oncology.

AGORA at the Heart of the CHUV

The construction of the AGORA – Cancer Center, which began in the fall, of 2015 is progressing rapidly. September 29, 2016 marks the official laying of the first stone of the AGORA – Cancer Center. The ceremony took place in the presence of three department heads of the Canton of Vaud, Anne-Catherine Lyon (DFJC)\(^1\), Pierre-Yves Maillard (DSAS)\(^2\), and Pascal Broulis (DFIRE)\(^3\), as well as representatives of various institutions. By the end of December 2016, four of the building’s seven floors had been completed. By the end of March 2017, the edifice was standing and the work on the inside of the building could begin. The first three months of 2018 will be devoted to the approval of the various technological platforms.

The ISREC Foundation hopes to inaugurate this new building in the spring of 2018. Close to 300 scientists and clinicians will then be able to unite their competences and combine their efforts in the fight against a disease that still affects four out of ten Swiss citizens at some point in their lives.

---

\(^{1}\) DFJC : education, youth and culture department
\(^{2}\) DSAS : health and social action department
\(^{3}\) DFIRE : department of finances and external relations
LIST OF KEY EVENTS IN 2016

1st semester

12.02
Death of Yves Paternot

18.02
Nomination of the new president, Catherine Labouchère

12.05
Nomination of a new Foundation Council member, Béatrice Schaad

Nomination of three new Foundation Council members, Dr Thomas Paulsen, M. Yves Bonzon and Prof. Pierre-Marie Glauser

Nomination of four new Scientific Council members, Prof. Fabrice André Prof. Michael Hall Prof. Peter Johnson Prof. Anne Müller

16.06
The excavation work for the AGORA building is completed

26.06
8th edition of the «Trophée AGO» soccer tournament in support of cancer research
## 2nd semester

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>03.07</td>
<td>Summer Research Program UNIL-EPFL: the ISREC Foundation supported 12 students (6 UNIL et 6 EPFL)</td>
</tr>
<tr>
<td>27.08</td>
<td>18th edition of the «Corcelles-le-Jorat en Gillet» motorcycle and sidecar race in support of cancer research</td>
</tr>
<tr>
<td>07.09</td>
<td>ISREC-SCCL inaugural symposium. As a member of the SSCL¹, the ISREC Foundation supported this event.</td>
</tr>
<tr>
<td>29.09</td>
<td>Foundation stone laying ceremony for the AGORA building</td>
</tr>
<tr>
<td>24.11</td>
<td>Salon Planète Santé</td>
</tr>
</tbody>
</table>

¹ SCCL: Swiss Cancer Center Lemanic

---

**Salon Planète Santé**
The ISREC Foundation was a partner of this event
Between 2008 and 2016 the ISREC Foundation awarded 10 PhD scholarships, funded 3 professorial chairs, 16 scientific research projects, 9 « Summer Research Programs » allowing 93 students from all over the world to take part in a 2 months scientific exchange, and supported 7 scientific conferences.

The Foundation thus disbursed 2,5 millions for education and the next generation of scientists; more than 18,5 millions for translational and oncological research projects; 9 millions were allocated to young promising professors; 0.5 million was spent on scientific summer programs, symposiums and scientific conferences.
Professor Franco Cavalli’s first contact with Lausanne dates back to 1989 when the CHUV asked him to become the director of its Oncology Department, an offer he unfortunately had to decline for family reasons. In his capacity as the president of the Swiss Cancer League and the Swiss Group for Clinical Cancer Research, it was during this period that he came into contact with the ISREC, which he believed to be one of the most active institutions in the support of cancer research projects.

Franco Cavalli then was engaged in various commissions and working groups in the Lausanne area, and at that time crossed paths with Yves Paternot, member of the ISREC Foundation Council, and its future president from 2005 to 2016, who invited him to become a member of ISREC’s Scientific Board. In 2005, Franco Cavalli took over the presidency of this board.

Since 2001, his mission is to coordinate scientific research and to find financial resources for scientists.

We thank Professor Franco Cavalli for taking time to answer a few questions.
At the present time, more than one out of every two individuals suffering from cancer will recover. Do you believe this rate can be further increased in the future?

I think it is important to be careful with predictions and not to become too optimistic. In 1971, the American president Nixon declared war on cancer and thought the disease would be eradicated within 10 years. Despite tremendous investments, this was not the case. We need to remain realistic: research progresses each year and certainly, one day, we will be able to heal more, if not all, cancers. At this point in time however, it is impossible to say whether this will be in 5, 10 or 50 years.

Do we know more about the mechanisms involved in the development of cancer today?

As cancer begins with a genetic modification (which later causes the uncontrolled development of abnormal cells), technologies allowing us to examine the human genome can tell us a great deal about this disease. They are the basis of the advances in knowledge on this subject. Now that we can «read» the genes, the speed at which we acquire information is increasing significantly. We have never learned more about cancer than in the past 15 years.

In terms of drug treatments, there has been a significant paradigm shift. Until now, the development of medical treatments followed an empirical line of reasoning: each year, chemists developed new, potentially effective anti-cancer substances which were then tested in cell lines, followed by animals and finally human beings.

Previously, it was not understood why the immune system does not destroy cancer cells. Today we know that cancer cells can block the «control points» that keep the immune system from attacking the organism’s healthy cells. This mechanism puts our self-defense system to sleep.

Scientists are therefore trying to develop substances that can either interact directly with this defect or modify the chain of chemical reactions that cause the growth of cancer cells. This has led to the development of so-called «checkpoint inhibitor» drugs which enable the cells to do their job. Earlier, cells had the gun but not the munition. With this technique, we are handing them the munition. Today, we are seeing results never observed before, positive reactions in tumors such as leukemia, against which nothing could be done so far.

How does the ISREC Foundation identify projects worthy of support?

The Foundation has always supported projects lacking clear financing but promising to be successful in the long term. It’s a bet on the future. We first promoted the biological approach, then immunology and lastly techniques related to molecular biology and genomics.

At the disciplinary level, it is clear that the emphasis will be placed on immunology and immunotherapy, disciplines that concern all types of cancers and that have always been
strong subjects in Lausanne. We will colla-
borate closely with the Ludwig Institute. The
director of the Lausanne branch, Profes-
sor George Coukos, head of the oncology
department at UNIL-CHUV, is a very expe-
rienced immunologist. With regard to the
CHUV, we will be working intensively on this
approach with Professor Solange Peters,
head of the medical oncology service and a
specialist in the area of thoracic cancers.
A workgroup at ISREC@epfl is also conduc-
ting research on malignant lymphomas and
tumors of the lymphatic system, cancers
that had hardly been studied in Lausanne
previously.

**Where does Switzerland stand in terms of cancer research?**

In the last 50 years, Switzerland has fallen
behind. It is important to know that in our
country research is financed by the Swiss
Confederation and treatments by the can-
tons. Because of this separation, it is diffi-
cult to combine theory and practice. In ad-
dition, Switzerland, unlike other countries,
does not have large, cancer-focused hospi-
tals which bring together basic, clinical and
translational research. The objective, confir-
med in a message released by the Swiss
Federal Council, is to turn this situation
around and to bring about collaborations.
The AGORA – Cancer Center perfectly fits
this political vision.

**How did the idea take shape to create AGORA, the new translational cancer research center financed by the ISREC Foundation?**

After having supported numerous projects,
the ISREC Foundation decided that isolated
projects are a good thing but that it was now
time to connect them and to create a kind
of incubator. Yes, I think this is the correct
word! In 2018, approximately 300 scientists
and clinicians from all partner institutions
will be brought together in a single building
in close proximity to the CHUV. This center
should contribute to an acceleration of the
development of novel therapeutic options
for cancer patients.

For 3 years now, the ISREC Foundation has
focused its efforts on the building of the
AGORA – Cancer Center.

**Why is proximity to a university hospital an important factor?**

The location on the site of the CHUV should
help reduce the intellectual distance be-
tween clinicians and scientists. Oftentimes,
clinicians, including myself when I was a
practitioner, see patients and ask themsel-
ves questions they are unable to answer.
That is what translational research is about:
jointly finding solutions to practical problems
encountered by physicians.

**How does the Scientific Board choose the projects it will support?**

So far, we have always supported 3 to 4
small projects per year. With AGORA, the
aim is to develop larger projects. Earlier,
scientists approached us with a project and
asked us to finance it. From now on, we will
audition projects born within the scope of
AGORA once a year and assess which ones
match the ISREC Foundation’s missions.
We will only select translational projects,
and to do so, it will be important to have a
good upstream vision of what the scientists are proposing. We will offer the scientists the optimal framework. From there on, it’s up to them to do the job!

**What does this mean in concrete terms?**

The multidisciplinary and international Scientific Board was enlarged to 5 members. One of its missions will be to visit AGORA once a year, in order to analyze ongoing projects, to audition scientists and to make sure the research is truly translational. The aim is to ensure that the financial input actually benefits the patients.

**How is the AGORA – Cancer Center perceived by Swiss professionals?**

Generally speaking, this project is a great opportunity for intercantonal collaborations. For example, cooperation is being set up with Geneva, which has many resources in the area of genomics. Within the next 50 years, this will certainly lead to a coordinated center. We have no other choice: infrastructure has become so expensive that we must collaborate if we want to compete with San Francisco, Stanford or Boston.

**Will these new methods be affordable for patients?**

This is a fundamental issue that means a lot to me. Society and politics need to deal with this problem. The cost of these novel treatments is tremendous. If we look at the evolution of costs over the last 25 years, it is clear that our system will not be able to support this development indefinitely. Being a scientist, this question is of particular interest to me: the risk is that in future only those who can afford to pay will receive treatment. This «two-class health-care system», already evident in the USA, is of course non-ethical. It is often said that physicians must solve this problem, but that is wrong. Society must implement laws to regulate the system.
Amélie Cachot
A 27-year-old Swiss ISREC Foundation grant holder in her second year in the «Cancer and Immunology» PhD program.

Amélie is conducting her research on the analysis of a new T lymphocyte candidate for immunotherapies of human tumors in Prof. Pedro Romero’s lab at LICR@UNIL.

″Providing answers for patients thanks to basic research″

Why cancer research?
Cancer is a reality that concerns all of us at some point. During my research, I was able to follow a clinical trial with melanoma patients. This experience enabled me to measure the impact of my work. I wish to discover solutions that will help fight this disease which so skillfully evades therapeutic advances.

What does the ISREC Foundation mean to you?
Thanks to the ISREC Foundation and its trusting donors, I can perform my research in an efficient and untroubled manner, without financial worries. The ISREC Foundation enables scientists to conduct their work independently, and provides visibility to scientific projects that are often confined to the laboratory.

How do you stay motivated?
There are, of course, more difficult periods when results are not coming in. But all it takes is one positive experiment to give us an impulse for the next step. The dialogue with my colleagues and the proximity to the CHUV and the university are important factors that contribute to the expertise one would not be able to acquire if working alone.

Your message to the patients?
Try to be patient, because we are making progress and are working very hard.
What is at stake in your work?
CD8 T cells contribute to the immune system’s ability to eliminate tumors naturally. However, this activity is often limited, as these cells do not always recognize their tumoral target with the appropriate intensity. Using an analogy, one can compare this situation to the strength put into a handshake: if it is too weak, it often signals lack of interest. In order to boost the striking potential of T cells, we have enhanced their affinity to their targets, generating a firm and honest handshake, so to speak. Interestingly, beyond a certain affinity threshold, the T cells’ function starts to weaken. In the same way, a too vigorous handshake is not a suitable way to send a good signal. The general aim of my project is to find out which molecules are responsible for this regulation and how they control T cell activation and function.

Your message to donators?
A donator is a visionary who has fully understood the need for research and investment in promising projects, even if this does not result in personal benefits.

How do you stay motivated?
Tiniest results keep me going on a daily basis. I try to keep in mind that the ultimate goal of our work is to facilitate the access of as many patients as possible to therapeutic innovations and thus to save an increasing number of lives.
Svenja Groeneveld  
A 29-year-old German ISREC Foundation grant holder in her third year in the «Molecular Life Sciences» PhD program.

Svenja is conducting her research on the role of the epithelial-to-mesenchymal transition in non-small cell lung cancer in Prof. Etienne Meylan’s lab at the EPFL/SV/ISREC.

Why are you interested in research?  
I was lucky to have been raised in a scientific environment. My parents, both of them science professors, awakened my interest in the life sciences at a very early age.

What is the ultimate goal of your work?  
Our lab is studying lung cancer, one of the deadliest cancers. More than 50% of all patients diagnosed with this illness have already developed numerous metastases. One of the reasons for this situation is the absence of symptoms at the beginning of the illness, which causes patients to consult their physician at a late stage.

We are studying a gene that seems to be involved in the generation of metastases. Our experiments are performed in mice, a species which presents various characteristics of the human form of the disease. Our work consists in activating, then deactivating this gene in order to determine the consequences on the evolution of the disease.

What does the ISREC Foundation mean to you?  
The ISREC Foundation is a key player in Swiss cancer research.

What three essential qualities are needed to perform research?  
Curiosity, tolerance to frustration and perseverance.
Pierpaolo Ginefra
A 31-year-old Italian ISREC Foundation grant holder in his fourth year in the «Molecular Life Sciences» PhD program.

Pierpaolo is conducting his research on the spatiotemporal control of proprotein convertases and the impact of growth factors on signaling pathways in Prof. Daniel Constam’s lab at the EPFL/SV/ISREC.

Who gave you your passion for research?
Prof. Umberto Veronesi, one of the most eminent Italian oncologists and a believer in a paradigm shift towards less invasive surgery, particularly with respect to the treatment of breast cancer. He is also one of the first specialists to have taken into account the psychological aspect of the disease and to have placed the patient at the center of the treatment.

Why cancer research?
I lost my father to cancer when I was just a child. The other reason is my interest in nature, plants in particular, which led me to study biology. I then wished to better understand this disease and its causes, in order to fight it more effectively and to help patients recover more frequently.

What is the ultimate goal of your work?
Do you know the game called Cluedo, in which the aim is to find the killer? Imagine a family of 5 living in a house. Each resident has a particular behavior and habits and plays a specific role. The same is true within a group of cells. In my work, I am studying the interactions between the different components of a cell in order to better understand their role or a potential malfunction that leads to a proliferation of cancer cells. I then look at all the pieces to find the culprit. And what if all this were programmed in advance?

Yours thoughts on the ISREC Foundation?
I associate the ISREC Foundation with AGORA. Physicians and biologists need to communicate because they are always better as a team, especially when it comes to cancer.

“AGORA will promote collaborations between scientists and clinicians”
As of 2018, the AGORA – Cancer Center will welcome more than 300 scientists and clinicians in an 11,500 m² space; 5,000 m² of laboratories and 2,900 m² of technological platforms will thus be made available to the scientists; the center will also include a 260 seat auditorium and numerous conference and seminar rooms; the estimated cost of the building is 80 millions Swiss francs; the project is made possible by the ISREC Foundation as well as by generous support from the Loterie Romande amounting to 3 millions Swiss francs, by the Leenaards Foundation amounting to 2.5 millions Swiss francs and by a substantial donation from the Göhner Foundation.
AGORA: THE FIRST STONE

Working Together to Fight Cancer

This translational cancer research center, named AGORA – Cancer Center, will open its doors in the spring of 2018 at the heart of the hospital campus. Initiated by the ISREC Foundation, the AGORA project is the result of a partnership between the CHUV, the University of Lausanne, the EPFL, the Ludwig Institute for Cancer Research and the University Hospitals of Geneva. AGORA aims to become a center of excellence that will attract the finest cancer specialists.
Allowing Patients to Benefit from Novel Treatments
On 11,500 m², the building will bring together the competences of approximately 300 scientists and clinicians from the partner institutions. Their goal will be to pool their efforts against a disease that still affects a large portion of the population and is one of the major public health issues worldwide.

A community of experts comprising physicians, biologists, geneticists, immunologists, bioinformaticians and bioengineers will work together under one roof to address the challenges posed by this disease. The center will help accelerate the development of novel therapeutic options for the needs of the patients.

Ensuring Continuing Medical Care with a Human Dimension
This partnership between institutions that have been working in close collaboration for several years will also contribute to the training of future scientists and clinicians. These individuals will benefit from an infrastructure that meets the highest medical requirements. At the heart of the AGORA – Cancer Center, an auditorium will welcome the best oncology specialists and will serve as a study space where young students can prepare to take over and ensure continuing medical care with a human dimension, in direct interaction with experienced researchers and clinicians.
ORGANISATION

FOUNDED ON JUNE 18, 1964, THE ISREC FOUNDATION IS A PRIVATE NON-PROFIT FOUNDATION.

Its mission is to select and support translational cancer research projects and, in doing so, to promote knowledge transfer and encourage collaborations between fundamental and clinical research.

These innovative projects make it possible to translate discoveries into results and to generate a positive impact on the future treatment of human cancer.

THE FOUNDATION CONSISTS OF THE FOLLOWING BODIES:

THE FOUNDATION COUNCIL

The Foundation Council is the highest managing authority of the Foundation. It allocates resources, appoints its members and those of the Scientific Board and the Management, as well as the Financial Auditors. It approves the annual budget and the Foundation accounts.

President
Catherine Labouchère
Jurist, delegate of the Canton of Vaud parliament

Members
Yves Henri Bonzon
Head Investment Management / CIO and member of the Executive Board, Julius Bär

Prof. Franco Cavalli
Representative of the Scientific Board, Scientific Director, IOSI (Istituto Oncologico della Svizzera Italiana, Bellinzona)

Prof. Pierre-Marie Glauser
Lawyer and professor of tax law at UNIL (University of Lausanne), Associate at Abels Oberson SA

Prof. Pierre-François Leyvraz
General Director, CHUV (Centre Hospitalier Universitaire Vaudois)

Prof. Philippe Moreillon
Vice-Rector, UNIL (University of Lausanne)

Dr Thomas W. Paulsen
CEO, Chief Financial Officer, Head of Finance and Risk Division, Banque Cantonale Vaudoise, Lausanne

Mme Béatrice Schaad
Director of the Communications Department, CHUV (Centre Hospitalier Universitaire Vaudois)

Prof. Didier Trono
Full Professor, GHI (Global Health Institute), EPFL (École Polytechnique Fédérale de Lausanne)

Prof. Thomas Zeltner
Former Director of the Federal Office for Public Health
THE SCIENTIFIC BOARD
The Scientific Board is composed of experts of international renown in various fields of cancer research.

President
Prof. Franco Cavalli
Director, IOSI (Istituto Oncologico della Svizzera Italiana)

Members
Prof. Fabrice André, MD, PhD
Research director, responsible for the U981 unit of the INSERM, Associate Professor, medical oncology department, Institut Gustave Roussy, Villejuif, France
Prof. Dr. Michael N. Hall
Professor at the Biozentrum, University of Basel
Prof. Peter Johnson
Professor of medical oncology, Faculty of Medicine, University of Southampton, UK
Prof. Dr. Anne Müller
Associate Professor in experimental medicine, Institute for Molecular Cancer Research, University of Zurich

The Management
Assisted by the Scientific Board, the Management selects the research projects to be funded, and presents its proposals to the Foundation Council. It develops and proposes a fundraising strategy and performs the tasks defined by the regulations of the Foundation.
Prof. Francis-Luc Perret, Director

The Financial Auditors
Ernst & Young SA, Lausanne

Thank you
Special thanks go to Prof. Francis-Luc Perret, director, to Aylin Niederberger, general secretary, Virginie Porret, communication assistant, and Nathalie Blanc, administration assistant, as well as our ambassadors Didier Grobet and Jürg Kärle for their faithful commitment.
Since 1964, several donors have supported through their gifts, subsidies, or legacies our cause and contributed to the progress of cancer research. We are very grateful and thank each one of them most warmly. Among these donors, more than five hundred appear in our gold book:

MORE THAN ONE MILLION FRANCs

One anonymous gift / One anonymous legacy, Lausanne / Legacy Anny B., Lausanne / Mrs. Annette B., Vevey / Mrs. Anne-Laurence B., Pully / Mrs. Nida D., Colombier / Mr. Dr. Dimiri D.,ully / Mrs. Johanna G., Lausanne / Göhner Foundation, Zug / Mrs. Jeanne H., Neuchâtel / Helmut Horton Foundation, Lugano / Mrs. Henriette H.-C., Lausanne / Mr. Jean-Pierre H., St. Mer / Larré Limited, Bermuda / Geneards Foundation, Lausanne / Swiss Cancer League, Bern / Loterie Romande, Lausanne / Mrs. Marie M., Martigny / Mrs. Yves P., Verbois / Pestalozzi Foundation, Vaduz / Portos Foundation, Vaduz / Mrs. Judith P., Lausanne / Mrs. Martine Monique R., Geneva / Mr. Eric S., Neuchâtel / Sevestropouli Fund, Lausanne / Mr. Marc V., Lausanne / Canton Vaud

BETWEEN CHF 100,000. – AND ONE MILLION FRANCs

Thirty-four anonymous gifts / Canton Aargau / Mrs. Charlotte B., Romandy / Mrs. Dina Henriette B., Vevey / Mrs. Anne-Laurence B., Pully / Mrs. Nida D., Colombier / Mr. Dimiri D.,ully / Mrs. Johanna G., Lausanne / Göhner Foundation, Zug / Mrs. Jeanne H., Neuchâtel / Helmut Horton Foundation, Lugano / Mrs. Henriette H.-C., Lausanne / Mr. Jean-Pierre H., St. Mer / Larré Limited, Bermuda / Geneards Foundation, Lausanne / Swiss Cancer League, Bern / Loterie Romande, Lausanne / Mrs. Marie M., Martigny / Mrs. Yves P., Verbois / Pestalozzi Foundation, Vaduz / Portos Foundation, Vaduz / Mrs. Judith P., Lausanne / Mrs. Martine Monique R., Geneva / Mr. Eric S., Neuchâtel / Sevestropouli Fund, Lausanne / Mr. Marc V., Lausanne / Canton Vaud

BETWEEN CHF 50,000. – AND CHF 100,000. –

Thirteen anonymous gifts / Mrs. Alice A., Montluçon / Mrs. Yvette A., Vevey / Allia Foundation, Tokyo / Mrs. Marie B., Pully / Mrs. Rachelle B., Montreux / Canton Basel-Land / Mr. Ernest B., Geneva / Mrs. Liliane B., Lausanne / Mrs. Germaine B.-R., Aubonne / Mr. Giovanni B., Lausanne / Centrale Suisse des Lettres de Gages (Pendantcentrale), Bern / Mrs. Violetta C., Lausanne / Mrs. Alice E., Orbe / Mr. Marcel C., Lausanne / Mrs. Teresa C.-B., Zürich / Mrs. Yvonne C., Lausanne / Mrs. Martine D., Lausanne / Mr. Jean D., Biel / Mrs. Raymond D., Morges / Mrs. Fernande D.-A., Les Cullayers / Ailes / Irène Eide-Liethinger Foundation, Bern / Emouna Foundation / Ernst & Young, Lausanne / Mrs. Marie E.-B., Cité-près-Câline / Alfred Fischer Foundation, Lausanne / Fabrique de Câbles Électriques, Courtalé / Mrs. Arlette F., Vevey / Mrs. Josette F., Neuchâtel / Mrs. Dorothea G., Lausanne / Mrs. Liliane G., Aubonne / Mrs. Claude G., New York / Mrs. Renée H., Lausanne / Mrs. Marie Juliette Simone H., Geneva / Mr. Jean-Charles H., Geneva / Mrs. Marguerite J., Lausanne / Prof. Gustave J., Zürich / Mrs. Marie-Louise J., Rennes / La Suisse Assurances, Lausanne / Foundation Les Halleux, Le Mont-Blanc, Lausanne / Mrs. Helene Meinrad L.-G., Cancer league Valais, Sierre / Mrs. Raymond M., Lausanne / Mrs. Marianne M., Lausanne / Mr. Eugen M.-M., Kliengberg / Nouvelé Cassius Foundation, Vaduz / Mrs. Andrée P., Lausanne / Mrs. Madeleine P., Bulle / Mrs. Emmanuelle P., F., Lausanne / Mrs. Gabrielle R., Aubonne / Mrs. Marianne R.-B., Fleury / Mrs. Anne-Marie S., Romandy / Téora Laval International, Yale / Mrs. Anne-Marie U., La Chaux-de-Fonds / Mrs. Madeline V., Les Pacocks / Mrs. Carine W., Lausanne / Legacy Stella 2, Lausanne / Mr. Pierre Z., Lausanne
BETWEEN CHF 5000.– AND CHF 50 000.

Fifty anonymous gifts / Mrs. Marie-A. D., Lausanne / Action cancer des boulangers / Mrs. Georgios, A., Colónbria / Mrs. Emilia A., Aix-les-Bain / Mrs. Jacqueline A., Lausanne / Albion House Ltd., Lausanne / Alcoa International SA, Lausanne / Dr. Elision A., Lausanne / André & Cie SA, Lausanne / Canton Appenzell Ausserrhoden / Association des Caisses Suisse, Zürich / Mrs. Charlotte B., Prilly / Mrs. Yvonne B., Nyon / Cie Anselm B., Lausanne / Mr. and Mrs. Alfred B., Boudry / Mrs. Elisabeth B., Lausanne / Mr. Maurice B., Boudry / Baumgartner Papiers SA, Lausanne / Mrs. Frédéric B., Clozans / Mrs. Marianne B., Yverdon / Mrs. Mireille B., Prilly / Mrs. Jeanne B., Romanel / Rhéa Foundation, Naucalbion / Mrs. Nicky B., Bué / Mrs. Rosa B., Cossonay / Mrs. Emma B., Bern / Robot & Fil, Lausanne / Mrs. Nicole B., Lausanne / Mrs. Clara B., Vevey / Mrs. Reina B., Prilly / Bois dart, Lausanne / Reconville / Mr. Yves B., Prilly / Mr. Bernard B., Ibermex / Mrs. Odile B., Lavaux / Mr. and Mrs. Michel B., Lausanne / Courier de Suisse Ursule, Sion / Mr. Ernst C., Villeneuve / Mr. and Mrs. Ernest D., Edithcarrara / Mrs. Simone M. D., Lausanne / Delta Securities, Gruyères / Mrs. Yolande de M., Évian / Miss Aida de P. M., Larnay / Belco De la Montagne, Lausanne / Mrs. Lily B., Lausanne / Mr. Xavier B., United Kingdom / Mrs. Ariane D., Genève / Mrs. Liva D., Montreux / Mr. Constant L., Lausanne / Mr. Émile D., Chablé St. Denis / Mrs. Alice D., Lausanne / Schwizeuraschische Stiftung für den Doron-Preis, Zug / Mrs. Fabienne D., Les Ponts-de-Martel / Dubois Invest, Lissmont / Étude Eudeedubli & Cie, Naucalbion / Mr. Jean D. / Mr. Albert D., Vevey / Mr. Armand D., Prétzlaz / Mr. Glen Andrews D., Épalinges / Bataash, Naucalbion / École hôtelière de Lausanne / Mrs. Madeleine E., Vevey / Mr. Roger E., Vevey / Empress Foundation, Zurich / Municipalité d’Épalinges / Établissement cantonal d’assurances, Pully / Fabrique d’Assurances Reusin, Vevey / Fabrique de Câbles de Brigny, Mrs. Francisca F., Lausanne / Mr. Raël F., Guglielmo / Mr. Pierré F., Romont / Mr. and Mrs. Pierré F., Vevey / FIM Foundation pour le Progrès de l’Homme, Lausanne / Mrs. Janine F., Vevey / Mrs. Jacqueline F.-G., Lausanne / Galerie SA, Bern / Mrs. Germaine G., La Tour-de-Peilz / Mr. Mario G., Villa / Mrs. Germaine Marie G., La Tour-de-Peilz / Mrs. and Mr. Caroline and Patrick G., St-Sulpice / Mr. Roger G., Larnay / Caron Clars / Galerie-Brulé & Cie, Lausanne / Mrs. Violette G., Lausanne / Mrs. Johanna G., Lausanne / Grande Kermesse de la jeunesse pour la lutte contre le cancer, Genève / Mrs. Hilda G., Morges / Mr. Daniel G. / Mrs. Françoise G., Lausanne / Mr. Gerhard H., Les Diabétiques / Louise Héllihirk Fonds, Lausanne / Mr. Gustav-H. H., Schaffhausen / Sources Minérales Henniez / Mrs. Violette H., La Touche-d’Orléans / Miss Marguerite H., Lausanne / Mrs. Yvette H., Lausanne / Mr. Ernst H., Biel / Mrs. Maryline P., Lausanne / Mrs. Z. H., Genève / Mrs. Claire-Marguerite H., Genève / Mrs. Helmut H., Lausanne / Impérinières Réunies SA, Lausanne / Integra Biosciences AG, Wallisellen / Interfood SA, Lausanne / Mrs. Ginette H., Prilly / Mr. and Mrs. Pierré J., Lausanne / Mrs. Josephine J., Siders / Mrs. Germaine J., Romont / Mr. Hermann J., Stä-Croix / Isarum Foundation / Mrs. Elisabeth J., Montreux / Mrs. Suzanne J., Frankreich / Mrs. Betty K., Genève / Rytmya Georgios Karinos Lamos Foundation, Lausanne / Mrs. Alice K., Grandvaux / Mrs. Rosa K., Crian-pièrs-Céligny / Kordel SA, Lausanne / La Bâloise-Assurances, Basile / Le Bulletin d’Occasions, Lausanne / La Genève Assurances, Genève / Mr. Charles-Eduoard L., Glénan / Mr. and Mrs. Lausanne, Lausanne / Mr. Roger L., Lausanne / Mrs. Sandra L., Lausanne / Mrs. Alice L., Payen / Laclanché SA, Vevey / Lemph SA, Écublens / Mr. Jean-Pierré L., Bouxoms / Mrs. Connie E.H. L., Zurich / Ligue genevoise contre le cancer, Genève / Ligue tessinoise contre le cancer, Locarno / Lo-Holding Lausanne-Ouchy SA, Lausanne / Mrs. Marlottel L., Montreux / Mrs. Emilie L., Lausanne / Mrs. Jane L., Lausanne / Mr. Hans L.-B., Hastie L., Burgdorf / Mr. Bertrand M., Genève / Mrs. Patricia M., Basel / Mr. J.-M., Lausanne / Mrs. Rachell M., Vevey / Mrs. Alice M., Château d’Oex / Mrs. Francis M., Lausanne / Mrs. Marie-Claire M., Lausanne / Emest Motzloy Foundation, Pully / Mr. Pierré M., Lausanne / Mrs. Viviane M., Genève / Metalwerke AG, Dorbach / Mr. Roland M., Grandvaux / Mrs. Martha M.-M., Montreux / Mrs. Léonie M., Lausanne / Mirog Genossenschafts-Bund, Zürich / Mrs. François M., Lausanne / Mrs. Suzanne M., Romont / Mrs. Nelly M., Rodegkas / Mrs. Charlotte M., Clagnay / Mrs. Angela N.-B., Bern / Mrs. Monique N., Vaudousvies / Nutreco SA, Penthalaz / ORFEO Foundation, Vaduz / Mrs. Marie G.-E., Lausanne / Mrs. Daniel D., Villars-sous-Vans / Payot SA, Lausanne / Mrs. Georges P., Morges / Mr. Jean P., Lausanne / Mr. René P., Lausanne / Legacy Violette P., Genève / Philippis AG, Zürich / Dr. Suzanne-Marie P.-R., Lausanne / Mrs. Kip, Cieris-aux-Bois / Mrs. Mireille P., Pully / Mrs. Rose-Marie P., St-Aubin-Sauvis / Mrs. Emilie P., Oron / Mr. Jean-Emile P., Orbe / The Pro Aretorica Trust / Publicis SA, Lausanne / Mrs. Elyo P., Pully / Mrs. Jeanne P., Fribourgs / Ramleit SA, Lausanne / Mrs. Angélle P., Payen / Mrs. Hansueli P., Bern / Mr. Alfred R., Aubermont / Renault Finance SA, Lausanne / Romestanstock, Zürich / Retaires Populaires, Lausanne / Mrs. Alice P., Lausanne / Mrs. Anne P., Lausanne / Mrs. Assim Alan-Jean & Daniel R., Bern / Mr. and Mrs. Hans & Hildegard R., Metersstocken / Montrose Reis SA, Geneva / Rotary Club, Lausanne / Roll Foundation, Luzern / Sagreve SA, Lausanne / Mr. and Mrs. David & Barbara S., Genève / Sandza S., Basle / Mrs. Jeanne S., La Conversion-sur-l’Ubay / Mr. Carl S., Montreux / Mr. S. S., Lausanne / Carrières Saisi, Saisi Combrond / Schüechzler SA, Montreux / Mr. Robert Charles S., Lausanne / Mr. Paul S., Lausanne / Mrs. Lucie S., Lausanne / Mrs. Clémence S., Lausanne / Mrs. Béatrice S., Lausanne / Mrs. Marguerite S., Lausanne / Mr. Gérard S., Suisse / Mr. Frédéric S., Pully / Mrs. Marguerite S., Lausanne / Mr. Gérard S., Suisse / Mr. Frédéric S., Pully / Mrs. Marguerite S., Lausanne / Mrs. Claire-Solange S., Genève / Mrs. Andi L., Cœtiora / Mrs. Delphine S., Lausanne / Mrs. Madeline S., Lausanne / Mrs. Claire-Marguerite S., Genève / Mrs. Helmut S., Lausanne / Impérinières Réunies SA, Lausanne / Integra Biosciences AG, Wallisellen / Interfood SA, Lausanne / Mrs. Ginette S., Prilly / Mr. and Mrs. Pierré S., Romont / Mr. and Mrs. Pierré S., Vevey / FIM Foundation pour le Progrès de l’Homme, Lausanne / Mrs. Janine S., Vevey / Mr. and Mrs. Jean S., St-Prex / Mrs. Megal S., Vevey / Mrs. and Mrs. Jean S., St-Prex / Supra (SVTAM), Lausanne / In Memory of Mrs. Jeanne S., Mont-Soleil / Mrs. Suzanne S., Lausanne / Team Girard, Veveydale/Village / Mrs. Madeleine T., Lausanne / Mrs. Jean T., St-Croix / Mr. Albert T., St-Saphorin-sur-Morges / The Rose Charitable Trust, United Kingdom / Trophée Agro, Lonay / Mr. Georges T., Lausanne / Mr. Alain T., Ecrin / Mrs. Antoinette T., Nyon / Elisabetta and Jacques Tabard Foundation, Lausanne / Mrs. Anne-Marie U., La Chaux-de-Fonds / Canton Uri / Miss Charlotte & Miss Helgevag, Davos / Mrs. Rosa V.-L., Langnau / Mr. Benjamin V., Cuffy / Vaudoise Assurances, Lausanne / Mrs. Constance V., Mont-Soleil / Mrs. Colette V., St-Sulpice / Mrs. Stéphanie de St-Pier SA / 24 Heures Presse, Lausanne / Mrs. Paulette V., Aximexier / Mrs. Nelly-Henriette V., Villeneuve / Mrs. Andrea V.D., Monthey / Vaudois SA, Bern / Mrs. Emmy W., St-Sulpice / Mrs. Lynn Elizabeth W., Montreux / Mr. Jacques W., Lausanne / Mrs. Geneviève W., Le Montreux / Winterthur Assurances, Zürich / Winti, Lausanne / JZelkinev SA, Genève / Zytas M., Nyon /